AbbVie Inc (ABBV)vsU.S. Physical Therapy, Inc. (USPH)
ABBV
AbbVie Inc
$294.64
-0.16%
HEALTHCARE · Cap: $520.47B
USPH
U.S. Physical Therapy, Inc.
$99.55
-0.05%
HEALTHCARE · Cap: $1.49B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 7855% more annual revenue ($66.01B vs $829.86M). ABBV leads profitability with a 15.7% profit margin vs 3.6%. ABBV appears more attractively valued with a PEG of 0.59. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
USPH
Hold43
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-87.6%
Fair Value
$157.25
Current Price
$294.64
$137.39 premium
Margin of Safety
+3.2%
Fair Value
$91.07
Current Price
$99.55
$8.48 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 36.6%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
No standout strengths identified
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 0.3% — below average capital efficiency
3.6% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 36.6%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : USPH
Revenue growth of 13.1% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.6x leaves little room for execution misses.
Bear Case : USPH
The primary concerns for USPH are Market Cap, Return on Equity, Profit Margin. Thin 3.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
ABBV profiles as a mature stock while USPH is a value play — different risk/reward profiles.
USPH carries more volatility with a beta of 1.13 — expect wider price swings.
USPH is growing revenue faster at 13.1% — sustainability is the question.
ABBV generates stronger free cash flow (7.3B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 43/100), backed by strong 15.7% margins and 10.3% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
U.S. Physical Therapy, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
US Physical Therapy, Inc. operates outpatient physical therapy clinics that provide preoperative and postoperative care and treatment for orthopedic-related disorders, sports-related injuries, preventive care, injured worker rehabilitation, and neurology-related injuries. The company is headquartered in Houston, Texas.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?